{"name":"Sucampo Pharma Americas, LLC","slug":"sucampo-pharma-americas-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Cohort 1: Lubiprostone Capsule, Fasted","genericName":"Cohort 1: Lubiprostone Capsule, Fasted","slug":"cohort-1-lubiprostone-capsule-fasted","indication":"Chronic idiopathic constipation","status":"phase_3"},{"name":"Lubiprostone 24","genericName":"Lubiprostone 24","slug":"lubiprostone-24","indication":"Chronic idiopathic constipation","status":"phase_3"}]}],"pipeline":[{"name":"Cohort 1: Lubiprostone Capsule, Fasted","genericName":"Cohort 1: Lubiprostone Capsule, Fasted","slug":"cohort-1-lubiprostone-capsule-fasted","phase":"phase_3","mechanism":"Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel motility.","indications":["Chronic idiopathic constipation","Opioid-induced constipation","Irritable bowel syndrome with constipation"],"catalyst":""},{"name":"Lubiprostone 24","genericName":"Lubiprostone 24","slug":"lubiprostone-24","phase":"phase_3","mechanism":"Lubiprostone is a ClC-2 chloride channel activator that increases intestinal fluid secretion and promotes bowel motility to relieve constipation.","indications":["Chronic idiopathic constipation","Irritable bowel syndrome with constipation (IBS-C)","Opioid-induced constipation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNbU1NR1JtUUZKdmo2RUhWV0c5OGVFSENrTmU2X3luemtRMHF0MmpDLV92MW5zYy1JUHBqbzd3NmJrUkxFWUxjYy1LcUh5NFU2cjlWX1VmZG1odWpILXRPYzFad056WDhEZkNVVlBPOWFHU3N0RlhFUk1ya3VIS1ZId0lCWEtqMmZNUVBQZGdwRElic3Qx?oc=5","date":"2025-12-15","type":"pipeline","source":"BioXconomy","summary":"Biotech Firms Announce Multiple CFO Changes - BioXconomy","headline":"Biotech Firms Announce Multiple CFO Changes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNdEk1YVVkRHR5Ql81djI1ZlpsclRCMVU5U1V2TjQ3MjBzVnNGTzFDSDlaTG5TVUtoSW1WOGZIOEhFVUJBTWw1eURiUFc4UElGRGtCa1lGRklWaHVjRVdjd045OHR3YkN5QzRPQ2NLNXdXR2d4OW5kSURHQnI0c0Y5WFU5S3FhVDd6YWp2UGlQVlZkc0lFQzdSRTNIMDB1TUo0ZmJn?oc=5","date":"2025-12-01","type":"pipeline","source":"Contract Pharma","summary":"Vistagen Names Nick Tressler as Chief Financial Officer - Contract Pharma","headline":"Vistagen Names Nick Tressler as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPaGZFSG82RGRWelRjakdvMUVzVDljS0lXamZzVXducG9TQ2FHNFU2dUxWcHVSLWN4cDVFdUVOYmQtajZ5WTgtVDBOaW8ya3NSeE1zV1dkU0tST1gtX0YzeHNjSDRTWjZzOW9oTFJlX1pEUmtab3dQaWhMWktGOHZZcjUxVEh3LVVOemFzX2VZRHFnTUhMcHF4LVJKQjQ4eUVmdGZ2MXZOLU9hX1ZzbTBhazE1R2NQcGJ0Q21n?oc=5","date":"2023-11-15","type":"pipeline","source":"statnews.com","summary":"Pioneering the Opioid-Induced Constipation (OIC) landscape for over 15 years - statnews.com","headline":"Pioneering the Opioid-Induced Constipation (OIC) landscape for over 15 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPbXR0YmxjUjd2NEFKLW5UdGdHR0JNZUwzUzQ2TXU4Z0g1MTVyVHF4Q1dMUXgwZUZhLU4tNmd0bmNiVm1rcU9JT1pYZS1MbF9zMjEzenJXa2NhaDZNdTQwYmhqdzRSRThXeXN0Um1MUFMydm94bGM1a0RmeWlHbkc4X2lHTnczNFVnNzJhcGRQRFNwejdUeTc3R1IwOFJ4UTh1Tkg1OXVRNGc4dmM1?oc=5","date":"2017-12-26","type":"deal","source":"Bloomberg.com","summary":"Mallinckrodt Adds New Drugs With $1.2 Billion Sucampo Deal - Bloomberg.com","headline":"Mallinckrodt Adds New Drugs With $1.2 Billion Sucampo Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNbGxJb2EyN3M1Vnhaa2F5Q3lweVZ4N3RyalF1YnY2bDM1ckpHZC12NnNIUERVZVhEekVXNDJBNlVMOFdLMi00OEJOYmp2SGs5ZDUyWm1vbU1KV25Gel9qWUF1dlR5ZldDLWlhWW9JWmJWT3lObEpldFFheHpEZjdzMWdtb21oRzd3N1RqbzgyYnZ6WVViOThwYlA3U2JUcTA?oc=5","date":"2017-04-03","type":"deal","source":"Fierce Biotech","summary":"Fledgling biotech Vtesse in $200M buyout from struggling Sucampo - Fierce Biotech","headline":"Fledgling biotech Vtesse in $200M buyout from struggling Sucampo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxONl96Z2ZkWGJKdkdXVXZCSGJWcnR6ZXdHaGVqRFJqTkdqMU84Qlg0M0xYaU1OY29oNW1la05oamNJcGVsT3NTbnA4SWVKRHFvWlhRUFV2alFTWEI1b1RxVW5BSmN4Zjd3REFia0pZQnZqSFh3N19haTlPWnhLNFpJNW5mUC1WcHJucGNKa1R4bDFta210Ujc0STdxNFRKR29wdFE?oc=5","date":"2015-03-31","type":"pipeline","source":"The Pharmaceutical Journal","summary":"Linaclotide, lubiprostone and prucalopride interactions - The Pharmaceutical Journal","headline":"Linaclotide, lubiprostone and prucalopride interactions","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}